EUR 115.88 For Business Accounts Only

Protalix BioTherapeutics Inc (PLX) - Financial Analysis Review

Summary

Protalix BioTherapeutics Inc (PLX) - Financial Analysis Review

Summary

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s pipeline products include PRX-102, a therapeutic enzyme for the treatment of Fabry disease; PRX-110, a plant cell-expressed recombinant form of human deoxyribonuclease I and is intended for the treatment of cystic fibrosis. Its PRX-106 is an orally delivered anti inflammatory treatment; and PRX-112, a oral glucocerebrosidase for gaucher disease.

GlobalData's Protalix BioTherapeutics Inc (PLX) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Protalix BioTherapeutics Inc Key Recent Developments:

Mar 16,2017: Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
Jan 09,2017: Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017
Dec 27,2016: Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
Nov 09,2016: Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results
Aug 08,2016: Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.